This study is looking at different doses of aspirin (81mg, 162mg, and 325mg) to see which is most effective for people with Chronic Obstructive Pulmonary Disease (COPD). Researchers believe that activated platelets, which are small blood cells involved in clotting, might also contribute to worse breathing symptoms in COPD. This trial will measure changes in specific markers in your urine and blood (urinary 11-dehydro-thromboxane B2 and serum thromboxane B2) over 10 weeks to understand how different aspirin doses affect these markers. You may be able to join if you are 40 to 80 years old, a former smoker with a significant smoking history, and have a specific lung function test result (FEV1/FVC < 0.7). The study is currently unclear on its recruitment status and plans to enroll 48 participants.

Study design

This is a randomized, double-blind, crossover study with 48 participants. You would receive each of the three aspirin doses in a specific order, with a break between each dose.

What's involved

You would take one aspirin pill daily and attend three follow-up visits after starting the study. At each visit, blood and urine samples will be collected.

Compensation

Not stated in the trial record.

Follow-up

You will have follow-up visits at two, six, and ten weeks after randomization.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.